AFLAflac Incorporated
Aflac Incorporated sells supplemental health insurance, primarily in the U.S., offering cancer, accident, and critical illness coverage to individuals and families. The next catalyst is Nov 4, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to navigate a cooling interest rate environment and sustain its margins amid a challenging insurance market.
- Aflac’s core business is underwriting supplemental health insurance, with a focus on high-margin, low-claim products.
- The company operates in a fragmented market with limited scale, but its brand recognition and product mix provide pricing power.
- Aflac’s recent focus on digital engagement and health education campaigns aims to drive long-term customer retention.
The schedule
- Wed4Nov
The Q3 2026 Earnings Release is a key event that could significantly impact the stock's performance. This event is expected to provide insights into the company's financial health and operational performance for the third quarter. Historical data suggests that the stock has shown a balanced reaction to such events, with a median path change of +6.99% and a drawdown of -3.26% over 38 similar events. Investors should closely monitor the earnings report and subsequent market reactions for potential trading opportunities.
- Tue9Feb
- Wed5May
- Fri6Aug
Past
- Fri7Aug
Actual outcome: Bear · $121.94 at outcome
Aflac reported Q2 earnings of $1.64 per share, matching the estimate of $1.64, but the stock fell 2.1% following the results. The earnings beat was overshadowed by weaker-than-expected Japan segment performance and FX headwinds, which pressured the stock. Additionally, the price closed below the bear floor of $121.50, reinforcing the bear classification.
Aflac reported Q2 earnings of $1.64 per share, matching the estimate of $1.64, but the stock fell 2.1% following the results. The earnings beat was overshadowed by weaker-than-expected Japan segment performance and FX headwinds, which pressured the stock. Additionally, the price closed below the bear floor of $121.50, reinforcing the bear classification.
- Wed18Mar
Actual outcome: Bear · $106.65 at outcome
Aflac's stock declined toward the $107.00 bear floor as the Bank of Japan's policy decision failed to provide a favorable shift for Yen-denominated earnings translation. This weakness was exacerbated by heavy institutional selling, including a 36.5% stake reduction by Barclays and repeated multi-million dollar share sales by major Japanese shareholder Post Holdings Co. Ltd. leading up to the event.
Aflac's stock declined toward the $107.00 bear floor as the Bank of Japan's policy decision failed to provide a favorable shift for Yen-denominated earnings translation. This weakness was exacerbated by heavy institutional selling, including a 36.5% stake reduction by Barclays and repeated multi-million dollar share sales by major Japanese shareholder Post Holdings Co. Ltd. leading up to the event.
- Wed25Feb
Actual outcome: Bull · $115.88 at outcome
Aflac reported Q4 EPS of $1.57, missing the $1.69 consensus estimate due to lower investment income and higher costs. However, the market overlooked the headline miss, focusing instead on the company's strong net earnings of $1.4 billion and the reiterated 5.2% increase in the first-quarter dividend. This strong signal of capital return and confidence in the 2026 outlook drove the stock significantly higher, clearing the $111.00 bull target.
Aflac reported Q4 EPS of $1.57, missing the $1.69 consensus estimate due to lower investment income and higher costs. However, the market overlooked the headline miss, focusing instead on the company's strong net earnings of $1.4 billion and the reiterated 5.2% increase in the first-quarter dividend. This strong signal of capital return and confidence in the 2026 outlook drove the stock significantly higher, clearing the $111.00 bull target.
